-

SHAREHOLDER INVESTIGATION: Robbins LLP Investigates Eargo, Inc. (EAR) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that it is investigating whether certain Eargo, Inc. (NASDAQ: EAR) officers and directors violated the Securities Exchange Act of 1934. A shareholder filed a class action alleging violations of the Securities Exchange Act of 1934 on behalf of all persons and entities that purchased or otherwise acquired Eargo securities between February 25, 2021 and September 22, 2021. Eargo is a medical device company that produces hearing aids.

Shareholders who purchased Eargo, Inc. (EAR) stock between February 25, 2021 and September 22, 2021, are encouraged to contact Robbins LLP for more information.

Eargo, Inc. (EAR) Allegedly Failed to Disclose it Improperly Sought Reimbursements from Third-Party Payors

According to the complaint, on August 12, 2021, Eargo revealed that claims submitted to the Company's largest third-party payor, which accounted for 80% of Eargo's accounts receivable, had not been paid since March 1, 2021. On this news, the Company's stock fell $8.00, or over 24%, to close at $24.70 per share on August 13, 2021. Then, on September 22, 2021, Eargo revealed "it is the target of a criminal investigation by the U.S. Department of Justice (the 'DOJ') related to insurance reimbursement claims the Company has submitted on behalf of customers covered by federal employee health plans." Moreover, the DOJ is the "principal contact related to the subject matter of the [ongoing] audit" of Eargo by an insurance company that is the Company's largest third-party payor. As a result, Eargo withdrew its full year guidance. On this news, Eargo's shares fell $14.81, or over 68%, to close at $6.86 per share on September 23, 2021.

If you suffered a loss due to Eargo, Inc.'s misconduct, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Eargo, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom